CPHI CHINA 2025 attracted global attention, serving not only as a top platform for industry exchanges but also as a grand showcase of cutting-edge products and technologies. An innovation storm in the pharmaceutical field is about to sweep through!
At this exhibition, Yifan Pharmaceutical brought a variety of blockbuster products.
China's first RYZNEUTA INJECTION, FOR CIN, simultaneously filed for approval in China, Europe, and the United States,
biological macromolecule APIs such as HUMAN GROWTH HORMONE (SOMATROPIN), TERIPARATIDE, INSULIN (ASPART, GLAGINE, DEGLUDEC), SEMAGLUTIDE AND LIRAGLUTIDE

During CPHI 2025 SHANGHAI, representatives from Yifan had in-depth discussions with potential partners, jointly exploring product application scenarios and business cooperation models, grasping the pulse of industry development, and uncovering unlimited business opportunities.
The exhibition time was limited, but innovation knows no bounds, and cooperation opportunities should not be missed!

We welcome all partners to stay in touch with us for win-win cooperation!

These products, with their outstanding quality and innovative technologies, received high attention and positive feedback from many professionals at the exhibition, fully demonstrating Yifan Pharmaceutical's profound strength and forward-looking layout in the pharmaceutical field.